BeOne Medicines (BEIGF) Revenue (2015 - 2026)

BeOne Medicines (BEIGF) has reported Revenue for 12 consecutive years, with $1.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Revenue rose 29.63% year-over-year to $1.7 billion in Q2 2026; TTM through Jun 2026 was $6.1 billion, a 34.35% increase from a year earlier, with the FY2025 full-year figure at $5.3 billion, up 40.23% from the prior year.
• Revenue was $1.7 billion for Q2 2026 at BeOne Medicines, up from $1.5 billion in the prior quarter.
• Over five years, Revenue peaked at $1.7 billion in Q2 2026 and troughed at $306.6 million in Q1 2022.
• A 5-year average of $902.6 million and a median of $855.2 million in 2023 frame the typical range for Revenue.
• The widest YoY moves for Revenue: up 127.73% in 2022, down 49.39% in 2022.
• Over 5 years, Revenue stood at $380.1 million in 2022, then soared by 66.91% to $634.4 million in 2023, then soared by 77.78% to $1.1 billion in 2024, then surged by 32.84% to $1.5 billion in 2025, then rose by 13.81% to $1.7 billion in 2026.
• The last three Revenue figures came in at $1.7 billion (Q2 2026), $1.5 billion (Q1 2026), and $1.5 billion (Q4 2025), per Business Quant data.